Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan
- PMID: 16168103
- PMCID: PMC1242123
- DOI: 10.1186/bcr1200
Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan
Abstract
Introduction: Although breast carcinoma (BC) is the most common malignancy affecting Jordanian females and the affected population in Jordan is younger than that in the West, no information is available on its biological characteristics. Our aims in this study are to evaluate the expression of estrogen receptor (ER) and progesterone receptor (PR) and Her-2/neu overexpression in BC in Jordan, and to compare the expression of these with other prognostic parameters for BC such as histological type, histological grade, tumor size, patients' age, and number of lymph node metastases.
Method: This is a retrospective study conducted in the Department of Pathology at Jordan University of Science and Technology. A confirmed 91 cases of BC diagnosed in the period 1995 to 1998 were reviewed and graded. We used immunohistochemistry to evaluate the expression of ER, PR, and Her-2. Immunohistochemical findings were correlated with age, tumor size, grade and axillary lymph node status.
Results: Her-2 was overexpressed in 24% of the cases. The mean age of Her-2 positive cases was 42 years as opposed to 53 years among Her-2 negative cases (p = 0.0001). Her-2 expression was inversely related to ER and PR expression. Her-2 positive tumors tended to be larger than Her-2 negative tumors with 35% overexpression among T3 tumors as opposed to 22% among T2 tumors (p = 0.13). Her-2 positive cases tended to have higher rates of axillary metastases, but this did not reach statistical significance. ER and PR positive cases were seen in older patients with smaller tumor sizes.
Conclusion: Her-2 overexpression was seen in 24% of BC affecting Jordanian females. Her-2 overexpression was associated with young age at presentation, larger tumor size, and was inversely related to ER and PR expression. One-fifth of the carcinomas were Her-2 positive and ER negative. This group appears to represent an aggressive form of BC presenting at a young age with large primary tumors and a high rate of four or more axillary lymph node metastases.
Figures

Similar articles
-
Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.World J Surg Oncol. 2008 Oct 22;6:112. doi: 10.1186/1477-7819-6-112. World J Surg Oncol. 2008. PMID: 18945339 Free PMC article.
-
Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.J Coll Physicians Surg Pak. 2009 Feb;19(2):99-103. J Coll Physicians Surg Pak. 2009. PMID: 19208313
-
Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.Breast J. 2005 Jul-Aug;11(4):278-80. doi: 10.1111/j.1075-122x.2005.21463.x. Breast J. 2005. PMID: 15982396
-
Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma.Breast Cancer Res Treat. 2012 Aug;135(1):29-37. doi: 10.1007/s10549-012-2047-z. Epub 2012 Apr 8. Breast Cancer Res Treat. 2012. PMID: 22484731 Review.
-
Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.Clin Breast Cancer. 2015 Oct;15(5):307-12. doi: 10.1016/j.clbc.2015.03.010. Epub 2015 Mar 25. Clin Breast Cancer. 2015. PMID: 25922284 Review.
Cited by
-
Postmenopausal Breast Cancer Risk in Relation to Antibodies Specific to Benzo[a]Pyrene, Estradiol and Progesterone.Iran J Cancer Prev. 2016 Apr 24;9(2):e4212. doi: 10.17795/ijcp-4212. eCollection 2016 Apr. Iran J Cancer Prev. 2016. PMID: 27482331 Free PMC article.
-
Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in women.Arch Med Sci. 2013 Jun 20;9(3):466-71. doi: 10.5114/aoms.2012.31010. Epub 2012 Oct 16. Arch Med Sci. 2013. PMID: 23847668 Free PMC article.
-
Evaluation of Immunohistochemical Profile of Breast Cancer for Prognostics and Therapeutic Use.Niger J Surg. 2018 Jul-Dec;24(2):100-106. doi: 10.4103/njs.NJS_2_18. Niger J Surg. 2018. PMID: 30283220 Free PMC article.
-
Correlation of Hormone Receptor and Human Epidermal Growth Factor Receptor-2/neu Expression in Breast Cancer with Various Clinicopathologic Factors.Indian J Med Paediatr Oncol. 2017 Oct-Dec;38(4):483-489. doi: 10.4103/ijmpo.ijmpo_98_16. Indian J Med Paediatr Oncol. 2017. PMID: 29333017 Free PMC article.
-
Unveiling HER2 immunoexpression in canine hepatoid gland neoplasms: clinicopathological and morphological associations.Int J Vet Sci Med. 2025 Apr 24;13(1):1-12. doi: 10.1080/23144599.2025.2495522. eCollection 2025. Int J Vet Sci Med. 2025. PMID: 40290666 Free PMC article.
References
-
- Jordan Cancer Registry, Ministry of Health. Cancer Incidence in Jordan 1997 Report. Amman. 2000.
-
- Dajani YF, Al-Jitawi SA. A study of 405 breast tumors in Jordanians using the revised WHO classification. Trop Geogr Med. 1987;39:182–186. - PubMed
-
- Amr SS. Breast diseases in Jordanian females: a study of 1000 cases. Eur J Surg Oncol. 1985;11:257–262. - PubMed
-
- Kamal MF. Cancer patterns in Jordan 1975–1979. Annals Chirurgiae Gunaecologiae. 1987;76:191–196. - PubMed
-
- Abalkhail AA, Zahawi HM, Almasri NM, Hameed OK. The role of young population structure in determining age distribution of breast cancer in Jordan. J Bahrain Med Society. 2003;15:28–33.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous